Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Importation bill hearing

Executive Summary

House Energy and Commerce Committee will hold a hearing Sept. 26 on "Food and Drug Import Safety Act of 2007" (H.R. 3610), introduced by Rep. John Dingell, D-Mich., Frank Pallone, D-N.J., and Bart Stupak, D-Mich. (1"The Pink Sheet" Aug. 13, 2007, p. 21). The bill authorizes $300 million for fiscal years 2008 through 2012 to pay for additional inspection personnel, labs and testing. Changes to the original draft include using fees to pay for overseas inspections and identifying the country of origin on foods, drugs and devices...

You may also be interested in...



Inspection Of Rx Imports Would Climb Under Bill Setting $300 Mil. In User Fees

Drug import fees totaling $300 million each in fiscal years 2008 through 2012 would be authorized by a food and drug import safety bill being developed by House Energy and Commerce Committee Chairman John Dingell, D-Mich

Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says

The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.

The Aspirin Test For AI?

US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS048820

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel